We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+18.89%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
+$357M
(+17%)
Cap. Flow
+$201M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MBX Biosciences
MBX
|
+$137M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$18M |
| 3 |
Oruka Therapeutics
ORKA
|
+$16.6M |
| 4 |
Alkermes
ALKS
|
+$15.4M |
| 5 |
Lexeo Therapeutics
LXEO
|
+$14.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$17.9M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$16.1M |
| 3 |
Vaxcyte
PCVX
|
+$14.4M |
| 4 |
Applied Therapeutics
APLT
|
+$10.7M |
| 5 |
PepGen
PEPG
|
+$9.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Miscellaneous | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Mereo BioPharma
MREO
$50.3M
| $21M | 0.84% |
5,097,779
+696,408
| +16% | +$2.88M |
2024 Q2
1 quarter
|
|
27
Silence Therapeutics
SLN
$577M
| $20.9M | 0.84% |
1,148,591
| – | – |
2022 Q1
10 quarters
|
|
|
28
Ascendis Pharma A/S
ASND
$15B
| $19.9M | 0.8% |
+133,333
| New | +$18M |
2024 Q3
0 quarters
|
|
29
DELISTED
HilleVax
HLVX
| $18.7M | 0.75% |
10,617,062
| – | – |
2022 Q2
9 quarters
|
|
30
DELISTED
Merus
MRUS
| $18.6M | 0.75% |
373,100
| – | – |
2022 Q1
10 quarters
|
|
31
Tyra Biosciences
TYRA
$1.32B
| $17.2M | 0.69% |
731,020
-101,200
| -12% | -$2.12M |
2022 Q1
10 quarters
|
|
32
Autolus Therapeutics
AUTL
$458M
| $16.8M | 0.67% |
4,623,324
| – | – |
2022 Q1
10 quarters
|
|
|
33
Alkermes
ALKS
$6.67B
| $16.1M | 0.65% |
+576,129
| New | +$15.4M |
2024 Q3
0 quarters
|
|
34
Immatics
IMTX
$1.09B
| $15.5M | 0.62% |
1,354,711
+202,255
| +18% | +$2.39M |
2024 Q2
1 quarter
|
|
|
35
Oruka Therapeutics
ORKA
$4.92B
| $11.7M | 0.47% |
+477,327
| New | +$16.6M |
2024 Q3
0 quarters
|
|
|
36
Lexeo Therapeutics
LXEO
$228M
| $11.3M | 0.45% |
+1,250,786
| New | +$14.9M |
2024 Q3
0 quarters
|
|
37
Design Therapeutics
DSGN
$636M
| $10.2M | 0.41% |
1,892,547
+697,368
| +58% | +$3.28M |
2024 Q2
1 quarter
|
|
38
Cogent Biosciences
COGT
$5.09B
| $10.1M | 0.41% |
936,576
| – | – |
2022 Q1
10 quarters
|
|
39
MacroGenics
MGNX
$213M
| $9.91M | 0.4% |
3,010,727
| – | – |
2023 Q1
6 quarters
|
|
40
DELISTED
Day One Biopharmaceuticals
DAWN
| $9.61M | 0.39% |
+689,655
| New | +$9.84M |
2024 Q3
0 quarters
|
|
41
Allogene Therapeutics
ALLO
$463M
| $8.03M | 0.32% |
2,867,750
| – | – |
2024 Q1
2 quarters
|
|
42
Puma Biotechnology
PBYI
$552M
| $7.81M | 0.31% |
3,062,558
| – | – |
2024 Q1
2 quarters
|
|
43
DELISTED
Adverum Biotechnologies
ADVM
| $7.51M | 0.3% |
1,069,244
| – | – |
2024 Q1
2 quarters
|
|
44
DELISTED
89bio
ETNB
| $7.4M | 0.3% |
1,000,000
| – | – |
2023 Q4
3 quarters
|
|
45
Acadia Pharmaceuticals
ACAD
$3.39B
| $7.23M | 0.29% |
470,338
| – | – |
2022 Q3
8 quarters
|
|
46
Arvinas
ARVN
$467M
| $7.03M | 0.28% |
285,331
| – | – |
2022 Q1
10 quarters
|
|
|
47
PepGen
PEPG
$176M
| $6.01M | 0.24% |
702,694
-800,094
| -53% | -$9.47M |
2024 Q1
2 quarters
|
|
48
DELISTED
Elevation Oncology
ELEV
| $3.6M | 0.14% |
5,993,579
+3,035,000
| +103% | +$4.5M |
2024 Q2
1 quarter
|
|
49
NewAmsterdam Pharma Warrant
NAMSW
| $3.5M | 0.14% |
500,333
| – | – |
2022 Q4
7 quarters
|
|
50
Immunocore
IMCR
$1.51B
| $3.39M | 0.14% |
108,762
| – | – |
2024 Q2
1 quarter
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2024 Portfolio in Review
As of Q3 2024, Frazier Life Sciences Management held 57 positions worth $2.5B, up 17% from $2.14B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Frazier Life Sciences Management deployed $201M of net new capital in Q3 2024, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was MBX Biosciences: 5,985,347 shares worth $155M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Edgewise Therapeutics, an estimated $17.9M trimmed.
- Frazier Life Sciences Management's largest Q3 2024 buy was MBX Biosciences: 5,985,347 shares worth $155M.
- Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q3 2024, an estimated $10.9M increase.
- Frazier Life Sciences Management's biggest Q3 2024 reduction was Edgewise Therapeutics, cutting an estimated $17.9M.
- Frazier Life Sciences Management fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $16.1M.
- Frazier Life Sciences Management's ten largest holdings make up 60% of its $2.5B portfolio in Q3 2024.
- Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2024.
- Frazier Life Sciences Management's portfolio value rose 17% quarter-over-quarter to $2.5B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.